The current guidelines heavily prioritize the early initiation and utilization of cardio-protective and renal-protective diabetes medications particularly SGLT2 and GLP1 irrespective of HBA1C (even if HBA1C is controlled) in particular, this would apply to patients who are recognized to have early stage heart failure during screening with natriuretic peptides. The gene discussed is GCG; the disease is heart failure.